Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00285077
Status:
COMPLETED
Last Update Posted:
2008-12-23
First Post:
2006-01-31
Brief Title:
Long-Term Safety Extension With SR57667B in Patients With Alzheimers Disease
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to assess the long term safetytolerability of 4 mgday of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimers Disease AD
A secondary objective is to describe the long term progression of Alzheimers symptoms in patients treated by 4 mgday of SR57667B
A secondary objective is to describe the long term progression of Alzheimers symptoms in patients treated by 4 mgday of SR57667B
Detailed Description:
Multinational multicenter randomized parallel-group double-blind phase II study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None